These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Pinzani M; Gentilini P Semin Liver Dis; 1999; 19(4):397-410. PubMed ID: 10643625 [TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and a Rational Basis of Therapy. Gracia-Sancho J; Maeso-Díaz R; Bosch J Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Gressner OA; Weiskirchen R; Gressner AM Clin Chim Acta; 2007 Jun; 381(2):107-13. PubMed ID: 17399697 [TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis: a dynamic and potentially reversible process. Povero D; Busletta C; Novo E; di Bonzo LV; Cannito S; Paternostro C; Parola M Histol Histopathol; 2010 Aug; 25(8):1075-91. PubMed ID: 20552556 [TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147 [TBL] [Abstract][Full Text] [Related]
11. Liver cirrhosis. Pinzani M; Rosselli M; Zuckermann M Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):281-90. PubMed ID: 21497745 [TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Ratti L; Pozzi M; Bosch J Dig Liver Dis; 2005 Nov; 37(11):886-93. PubMed ID: 16172033 [TBL] [Abstract][Full Text] [Related]
14. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Guyot C; Lepreux S; Combe C; Doudnikoff E; Bioulac-Sage P; Balabaud C; Desmoulière A Int J Biochem Cell Biol; 2006 Feb; 38(2):135-51. PubMed ID: 16257564 [TBL] [Abstract][Full Text] [Related]
15. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes. Ma R; Chen J; Liang Y; Lin S; Zhu L; Liang X; Cai X Biomed Pharmacother; 2017 Apr; 88():459-468. PubMed ID: 28122312 [TBL] [Abstract][Full Text] [Related]
16. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Mallat A; Lotersztajn S Am J Physiol Cell Physiol; 2013 Oct; 305(8):C789-99. PubMed ID: 23903700 [TBL] [Abstract][Full Text] [Related]
17. Hepatic stellate cells as a target for the treatment of liver fibrosis. Bataller R; Brenner DA Semin Liver Dis; 2001 Aug; 21(3):437-51. PubMed ID: 11586471 [TBL] [Abstract][Full Text] [Related]
18. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. Li D; Friedman SL J Gastroenterol Hepatol; 1999 Jul; 14(7):618-33. PubMed ID: 10440206 [TBL] [Abstract][Full Text] [Related]
19. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Svegliati-Baroni G; De Minicis S; Marzioni M Liver Int; 2008 Sep; 28(8):1052-64. PubMed ID: 18783548 [TBL] [Abstract][Full Text] [Related]
20. [Pathology of liver cirrhosis and portal hypertension]. Bläker H; Theuer D; Otto HF Radiologe; 2001 Oct; 41(10):833-9. PubMed ID: 11715574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]